Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2011 - 2026)

Neurocrine Biosciences (NBIX) has reported Other Accumulated Expenses for 16 consecutive years, with $66.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 16.55% year-over-year to $66.2 million; the trailing twelve-month figure through Jun 2026 stood at $66.2 million (up 16.55% YoY), and the FY2025 full-year result was $69.1 million, up 49.89% from the prior year.
• Other Accumulated Expenses grew to $66.2 million in Q2 2026 per NBIX's latest filing, from $58.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $69.1 million in Q4 2025 and bottomed at $17.6 million in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $37.9 million across 5 years, with a median of $36.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses slipped 9.5% in 2022, then jumped 99.46% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $20.7 million in 2022, then jumped by 73.43% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then soared by 49.89% to $69.1 million in 2025, then dropped by 4.2% to $66.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $66.2 million, $58.7 million, and $69.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.